Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Review Article

Innovation and Patenting Activities During COVID-19 and Advancement of Biochemical and Molecular Diagnosis in the Post- COVID-19 Era

Author(s): Suman Kumar Ray and Sukhes Mukherjee*

Volume 18, Issue 3, 2024

Published on: 27 September, 2023

Page: [210 - 226] Pages: 17

DOI: 10.2174/0118722083262217230921042127

Price: $65

Abstract

The COVID-19 pandemic is to escalate globally and acquire new mutations quickly, so accurate diagnostic technologies play a vital role in controlling and understanding the epidemiology of the disease. A plethora of technologies acquires diagnosis of individuals and informs clinical management of COVID. Some important biochemical parameters for COVID diagnosis are the elevation of liver enzymes, creatinine, and nonspecific inflammatory markers such as C-reactive protein (CRP) and Interleukin 6 (IL-6). The main progression predictors are lymphopenia, elevated D-dimer, and hyperferritinemia, although it is also necessary to consider LDH, CPK, and troponin in the marker panel of diagnosis. Owing to the greater sensitivity and accuracy, molecular technologies such as conventional polymerase chain reaction (PCR), reverse transcription (RT)-PCR, nested PCR, loop-mediated isothermal amplification (LAMP), and xMAP technology have been extensively used for COVID diagnosis for some time now. To make so many diagnostics accessible to general people, many techniques may be exploited, including point of care (POC), also called bedside testing, which is developing as a portable promising tool in pathogen identification. Some other lateral flow assay (LFA)-centered techniques like SHERLOCK, CRISPR-Cas12a (AIOD-CRISPR), and FNCAS9 editor limited uniform detection assay (FELUDA), etc. have shown auspicious results in the rapid detection of pathogens. More recently, low-cost sequencing and advancements in big data management have resulted in a slow but steady rise of next-generation sequencing (NGS)-based approaches for diagnosis that have potential relevance for clinical purposes and may pave the way toward a better future. Due to the COVID-19 pandemic, various institutions provided free, specialized websites and tools to promote research and access to critically needed advanced solutions by alleviating research and analysis of data within a substantial body of scientific and patent literature regarding biochemical and molecular diagnosis published since January 2020. This circumstance is unquestionably unique and difficult for anyone using patent information to find pertinent disclosures at a specific date in a trustworthy manner.

Keywords: COVID-19, inflammatory markers, molecular diagnosis, RT-PCR, LAMP, CRISPR, NGS, patents.

Graphical Abstract
[1]
Ray SK, Mukherjee S. Understanding the role of corona virus based on current scientific evidence - a review with emerg-ing importance in pandemic. Recent Patents Anti-Infect Drug Disc 2020; 15(2): 89-103.
[http://dx.doi.org/10.2174/1574891X15999200918144833] [PMID: 32957894]
[2]
Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 2020; 10: 587269.
[http://dx.doi.org/10.3389/fcimb.2020.587269] [PMID: 33324574]
[3]
Ray SK, Mukherjee S. COVID-19-Associated mucormycosis, A new incident in recent time: Is an emerging disease in the near future impending? Avicenna J Med 2021; 11(4): 210-6.
[http://dx.doi.org/10.1055/s-0041-1735383] [PMID: 34881204]
[4]
Mukherjee S, Ray SK. From bench side to bed-travelling on a road to get a safe and effective vaccine against COVID-19, day to save the life. Recent Pat Biotechnol 2022; 16(1): 2-5.
[http://dx.doi.org/10.2174/1872208315666211209094457] [PMID: 34886784]
[5]
Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed 2020; 91(1): 157-60.
[http://dx.doi.org/10.23750/abm.v91i1.9397] [PMID: 32191675]
[6]
Ray SK, Mukherjee S. The spectrum of biochemical alterations with molecular and serological biomarkers in the diagnosis of COVID-19: Searching for novel one to identify disease earlier with better prognosis and drug discovery. Recent Pat Antiinfect Drug Discov 2021; 16(3): 179-81.
[http://dx.doi.org/10.2174/2772434416666211122112743] [PMID: 34809554]
[7]
a) Goudouris ES. Laboratory diagnosis of COVID-19. J Pediatr 2021; 97(1): 7-12.
[http://dx.doi.org/10.1016/j.jped.2020.08.001] [PMID: 32882235];
b) Li W, Hong W. Methods for diagnosis and treatment of COVID-19. WO Patent 2022159429A1, 2022.
[8]
Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 – A systematic review. Life Sci 2020; 254: 117788.
[http://dx.doi.org/10.1016/j.lfs.2020.117788] [PMID: 32475810]
[9]
Zhang L, Guo H. Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Adv in Biomarker Sci and Technol 2020; 2: 1-23.
[http://dx.doi.org/10.1016/j.abst.2020.08.001] [PMID: 33511330]
[10]
Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci 2020; 57(6): 389-99.
[http://dx.doi.org/10.1080/10408363.2020.1770685] [PMID: 32503382]
[11]
Zhang B, Yu Y, Hubert SM, et al. Prognostic value of pro-inflammatory neutrophils and C-reactive protein in cancer patient with coronavirus disease 2019: A multi-center, retrospective study. Front Pharmacol 2020; 11: 576994.
[http://dx.doi.org/10.3389/fphar.2020.576994] [PMID: 33192519]
[12]
Mahat RK, Panda S, Rathore V, Swain S, Yadav L, Sah SP. The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis. Clin Epidemiol Glob Health 2021; 11: 100727.
[http://dx.doi.org/10.1016/j.cegh.2021.100727] [PMID: 33778183]
[13]
Mukherjee S, Ray SK, Kotnis A, Kanwar JR. Elucidating the role of cardiac biomarkers in COVID-19: A narrative evaluation with clinical standpoints and a pragmatic approach for therapeutics. Curr Cardiol Rev 2022; 18(4): e220222201354.
[http://dx.doi.org/10.2174/1573403X18666220222144002] [PMID: 35196971]
[14]
Gong J, Dong H, Xia QS, et al. Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: A retrospective study. BMC Infect Dis 2020; 20(1): 963.
[http://dx.doi.org/10.1186/s12879-020-05681-5] [PMID: 33349241]
[15]
Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev 2020; 53: 38-42.
[http://dx.doi.org/10.1016/j.cytogfr.2020.04.002] [PMID: 32360420]
[16]
Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: A retro-spective and observational study. Aging 2020; 12(12): 11245-58.
[http://dx.doi.org/10.18632/aging.103372] [PMID: 32633729]
[17]
Yamamoto A, Wada H, Ichikawa Y, et al. Evaluation of biomarkers of severity in patients with COVID-19 infection. J Clin Med 2021; 10(17): 3775.
[http://dx.doi.org/10.3390/jcm10173775] [PMID: 34501223]
[18]
Mirmoeeni S, Azari Jafari A, Hashemi SZ, et al. Cardiovascular manifestations in COVID-19 patients: A systematic review and meta-analysis. J Cardiovasc Thorac Res 2021; 13(3): 181-9.
[http://dx.doi.org/10.34172/jcvtr.2021.30] [PMID: 34630964]
[19]
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18(4): 844-7.
[http://dx.doi.org/10.1111/jth.14768] [PMID: 32073213]
[20]
Radford AD, Chapman D, Dixon L, Chantrey J, Darby AC, Hall N. Application of next-generation sequencing technologies in virology. J Gen Virol 2012; 93(9): 1853-68.
[http://dx.doi.org/10.1099/vir.0.043182-0] [PMID: 22647373]
[21]
Houldcroft CJ, Beale MA, Breuer J. Clinical and biological insights from viral genome sequencing. Nat Rev Microbiol 2017; 15(3): 183-92.
[http://dx.doi.org/10.1038/nrmicro.2016.182] [PMID: 28090077]
[22]
John G, Sahajpal NS, Mondal AK, et al. Next-generation sequencing (NGS) in COVID-19: A tool for SARS-CoV-2 diagnosis, monitoring new strains and phylodynamic modeling in molecular epidemiology. Curr Issues Mol Biol 2021; 43(2): 845-67.
[http://dx.doi.org/10.3390/cimb43020061] [PMID: 34449545]
[23]
Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: The disease and tools for detection. ACS Nano 2020; 14(4): 3822-35.
[http://dx.doi.org/10.1021/acsnano.0c02624] [PMID: 32223179]
[24]
Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25(3): 2000045.
[http://dx.doi.org/10.2807/1560-7917.ES.2020.25.3.2000045] [PMID: 31992387]
[25]
Chan JFW, Yip CCY, To KKW, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol 2020; 58(5): e00310-20.
[http://dx.doi.org/10.1128/JCM.00310-20] [PMID: 32132196]
[26]
Rahimi H, Salehiabar M, Barsbay M, et al. CRISPR systems for COVID-19 diagnosis. ACS Sens 2021; 6(4): 1430-45.
[http://dx.doi.org/10.1021/acssensors.0c02312] [PMID: 33502175]
[27]
Ganbaatar U, Liu C. CRISPR-based COVID-19 testing: Toward next-generation point-of-care diagnostics. Front Cell Infect Microbiol 2021; 11: 663949.
[http://dx.doi.org/10.3389/fcimb.2021.663949] [PMID: 33996635]
[28]
Ullah MF, Ali Y, Khan MR, et al. A review of COVID-19: Treatment strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. Saudi J Biol Sci 2022; 29(2): 860-71.
[http://dx.doi.org/10.1016/j.sjbs.2021.10.020] [PMID: 34658640]
[29]
Koczula KM, Gallotta A. Lateral flow assays. Essays Biochem 2016; 60(1): 111-20.
[http://dx.doi.org/10.1042/EBC20150012] [PMID: 27365041]
[30]
Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Sci 2018; 360(6387): 439-44.
[http://dx.doi.org/10.1126/science.aaq0179] [PMID: 29449508]
[31]
Islam KU, Iqbal J. An update on molecular diagnostics for COVID-19. Front Cell Infect Microbiol 2020; 10: 560616.
[http://dx.doi.org/10.3389/fcimb.2020.560616] [PMID: 33244462]
[32]
Ding X, Yin K, Li Z, Liu C. All-in-One Dual CRISPR-Cas12a (AIOD-CRISPR) Assay: A Case for Rapid, Ultrasensitive and visual detection of novel coronavirus SARS-CoV-2 and HIV virus. bioRxiv 2020; 2020.03.19.998724.
[http://dx.doi.org/10.1101/2020.03.19.998724]
[33]
WIPO’s COVID-19 Response. Available at: https://www.wipo.int/covid-19/en/ (Accessed on: May 13, 2023).
[34]
Wu X, Khazin B. Patent-related actions taken in WTO Members in response to the COVID-19 pandemic WTO, research and analysis, working papers, staff working paper. ERSD-2020-14,
[35]
Khachigian LM. Pharmaceutical patents: Reconciling the human right to health with the incentive to invent. Drug Discov Today 2020; 25(7): 1135-41.
[http://dx.doi.org/10.1016/j.drudis.2020.04.009] [PMID: 32325020]
[36]
Tietze F, Vimalnath P, Aristodemou L, Molloy J. Crisis-critical intellectual property: Findings from the COVID-19 pandemic. IEEE Trans Eng Manage 2022; 69(5): 2039-56.
[http://dx.doi.org/10.1109/TEM.2020.2996982] [PMID: 35938060]
[37]
Falciola L, Barbieri M. Searching and analyzing patent-relevant COVID-19 information. World Pat Inf 2022; 68: 102094.
[http://dx.doi.org/10.1016/j.wpi.2022.102094]
[38]
BioEcho receives patent for its EchoLUTION™ technology in the U.S. and Japan. Available at: https://www.news-medical.net/news/20230217/BioEcho-receives-patent-for-its-EchoLUTIONe284a2-technology-in-the-US-and-Japan.aspx (Accessed on: May 13, 2023).
[39]
Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020; 58(7): 1131-4.
[http://dx.doi.org/10.1515/cclm-2020-0198] [PMID: 32119647]
[40]
Kubina R, Dziedzic A. Molecular and Serological Tests for COVID-19. A comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics 2020; 10(6): 434.
[http://dx.doi.org/10.3390/diagnostics10060434] [PMID: 32604919]
[41]
El-Shabrawy M, Alsadik ME, El-Shafei M, et al. Interleukin-6 and C-reactive protein/albumin ratio as predictors of COVID-19 severity and mortality. Egypt J Bronchol 2021; 15(1): 5.
[http://dx.doi.org/10.1186/s43168-021-00054-1]
[42]
Letelier P, Encina N, Morales P, et al. Role of biochemical markers in the monitoring of COVID-19 patients. J Med Biochem 2021; 40(2): 115-28.
[http://dx.doi.org/10.5937/jomb0-29341] [PMID: 33776561]
[43]
Ghahramani S, Tabrizi R, Lankarani KB, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: A systematic review and meta-analysis. Eur J Med Res 2020; 25(1): 30.
[http://dx.doi.org/10.1186/s40001-020-00432-3] [PMID: 32746929]
[44]
Darif D, Hammi I, Kihel A, El Idrissi Saik I, Guessous F, Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog 2021; 153: 104799.
[http://dx.doi.org/10.1016/j.micpath.2021.104799] [PMID: 33609650]
[45]
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 2020; 54: 62-75.
[http://dx.doi.org/10.1016/j.cytogfr.2020.06.001] [PMID: 32513566]
[46]
Gao YM, Xu G, Wang B, Liu BC. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med 2021; 289(2): 147-61.
[http://dx.doi.org/10.1111/joim.13144] [PMID: 32696489]
[47]
Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020; 55: 102763.
[http://dx.doi.org/10.1016/j.ebiom.2020.102763] [PMID: 32361250]
[48]
Socorro FS, Fernandes PC Jr, Barbosa SMJ, et al. The neutrophil-to-lymphocyte ratio: A narrative review. Ecancermedicalscience 2016; 10: 702.
[http://dx.doi.org/10.3332/ecancer.2016.702] [PMID: 28105073]
[49]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[50]
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-8.
[http://dx.doi.org/10.1093/cid/ciaa248] [PMID: 32161940]
[51]
Carter LJ, Garner LV, Smoot JW, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci 2020; 6(5): 591-605.
[http://dx.doi.org/10.1021/acscentsci.0c00501] [PMID: 32382657]
[52]
Fung J, Lau SKP, Woo PCY. Antigen capture enzyme-linked immunosorbent assay for detecting middle east respiratory syndrome coronavirus in humans. Methods Mol Biol 2020; 2099: 89-97.
[http://dx.doi.org/10.1007/978-1-0716-0211-9_7] [PMID: 31883089]
[53]
Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral responses and serological assays in SARS-CoV-2 infections. Front Immunol 2020; 11: 610688.
[http://dx.doi.org/10.3389/fimmu.2020.610688] [PMID: 33391281]
[54]
To KKW, Tsang OTY, Yip CCY, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020; 71(15): 841-3.
[http://dx.doi.org/10.1093/cid/ciaa149] [PMID: 32047895]
[55]
Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect 2020; 9(1): 469-73.
[http://dx.doi.org/10.1080/22221751.2020.1732837] [PMID: 32102625]
[56]
Li C, Debruyne DN, Spencer J, et al. Highly sensitive and full-genome interrogation of SARS-CoV-2 using multiplexed PCR enrichment followed by next-generation sequencing. BioRxiv 2020.
[http://dx.doi.org/10.1101/2020.03.12.988246]
[57]
Sedlak RH, Jerome KR. Viral diagnostics in the era of digital polymerase chain reaction. Diagn Microbiol Infect Dis 2013; 75(1): 1-4.
[http://dx.doi.org/10.1016/j.diagmicrobio.2012.10.009] [PMID: 23182074]
[58]
Suo T, Liu X, Feng J, et al. ddPCR: A more accurate tool for SARS-CoV-2 detection in low viral load specimens. Emerg Microbes Infect 2020; 9(1): 1259-68.
[http://dx.doi.org/10.1080/22221751.2020.1772678] [PMID: 32438868]
[59]
Zheng J. SARS-CoV-2: An emerging coronavirus that causes a global threat. Int J Biol Sci 2020; 16(10): 1678-85.
[http://dx.doi.org/10.7150/ijbs.45053] [PMID: 32226285]
[60]
Marquez S, Prado-Vivar B, Guadalupe JJ, et al. Genome sequencing of the first SARS-CoV-2 reported from patients with COVID-19 in ecuador. medRxiv 2020; 2020.06.11.20128330.
[http://dx.doi.org/10.1101/2020.06.11.20128330]
[61]
Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 2020; 39(9): 1629-35.
[http://dx.doi.org/10.1007/s10096-020-03899-4] [PMID: 32333222]
[62]
Oude Munnink BB, Nieuwenhuijse DF, Stein M, et al. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands. Nat Med 2020; 26(9): 1405-10.
[http://dx.doi.org/10.1038/s41591-020-0997-y] [PMID: 32678356]
[63]
Park GS, Maeng JS. A novel isothermal method for amplification of long specific amplicon from linear template. Sci Rep 2022; 12(1): 2756.
[http://dx.doi.org/10.1038/s41598-022-06785-5] [PMID: 35177762]
[64]
Obande GA, Banga Singh KK. Current and future perspectives on isothermal nucleic acid amplification technologies for diagnosing Infections. Infect Drug Resist 2020; 13: 455-83.
[http://dx.doi.org/10.2147/IDR.S217571] [PMID: 32104017]
[65]
Abd El Galil KH, El Sokkary MA, Kheira SM, et al. Real-time nucleic acid sequence-based amplification assay for detection of hepatitis A virus. Appl Environ Microbiol 2005; 71(11): 7113-6.
[http://dx.doi.org/10.1128/AEM.71.11.7113-7116.2005] [PMID: 16269748]
[66]
Keightley MC, Sillekens P, Schippers W, Rinaldo C, George KS. Real-time NASBA detection of SARS-associated coro-navirus and comparison with real-time reverse transcription-PCR. J Med Virol 2005; 77(4): 602-8.
[http://dx.doi.org/10.1002/jmv.20498] [PMID: 16254971]
[67]
Hu X, Deng Q, Li J, et al. Development and clinical application of a rapid and sensitive loop-mediated isothermal amplification test for SARS-CoV-2 infection. MSphere 2020; 5(4): e00808-20.
[http://dx.doi.org/10.1128/mSphere.00808-20] [PMID: 32848011]
[68]
Soroka M, Wasowicz B, Rymaszewska A. Loop-mediated isothermal amplification (LAMP): The better sibling of PCR? Cells 2021; 10(8): 1931.
[http://dx.doi.org/10.3390/cells10081931] [PMID: 34440699]
[69]
Kashir J, Yaqinuddin A. Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19. Med Hypotheses 2020; 141: 109786.
[http://dx.doi.org/10.1016/j.mehy.2020.109786] [PMID: 32361529]
[70]
Park GS, Ku K, Baek SH, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Mol Diagn 2020; 22(6): 729-35.
[http://dx.doi.org/10.1016/j.jmoldx.2020.03.006] [PMID: 32276051]
[71]
Gorzalski AJ, Tian H, Laverdure C, et al. High-Throughput Transcription-mediated amplification on the Hologic Panther is a highly sensitive method of detection for SARS-CoV-2. J Clin Virol 2020; 129: 104501.
[http://dx.doi.org/10.1016/j.jcv.2020.104501] [PMID: 32619959]
[72]
Zhang Y, Garner R, Salehi S, Rocca ML, Duncan D. Molecular and antigen tests, and sample types for diagnosis of COVID-19: A review. Future Virol 2022; 17(9): 675-85.
[http://dx.doi.org/10.2217/fvl-2021-0256] [PMID: 35783674]
[73]
Yang W, Dang X, Wang Q, et al. Rapid detection of SARS-CoV-2 using reverse transcription RT-LAMP method. MedRxiv 2020.
[http://dx.doi.org/10.1101/2020.03.02.20030130]
[74]
Luppa PB, Müller C, Schlichtiger A, Schlebusch H. Point-of-care testing (POCT): Current techniques and future perspectives. Trends Analyt Chem 2011; 30(6): 887-98.
[http://dx.doi.org/10.1016/j.trac.2011.01.019] [PMID: 32287536]
[75]
St John A, Price CP. Existing and emerging technologies for point-of-care testing. Clin Biochem Rev 2014; 35(3): 155-67.
[PMID: 25336761]
[76]
Kim H, Chung DR, Kang M. A new point-of-care test for the diagnosis of infectious diseases based on multiplex lateral flow immunoassays. Analyst 2019; 144(8): 2460-6.
[http://dx.doi.org/10.1039/C8AN02295J] [PMID: 30849145]
[77]
Sadeghi P, Sohrabi H, Hejazi M, et al. Lateral flow assays (LFA) as an alternative medical diagnosis method for detection of virus species: The intertwine of nanotechnology with sensing strategies. Trends Analyt Chem 2021; 145: 116460.
[http://dx.doi.org/10.1016/j.trac.2021.116460] [PMID: 34697511]
[78]
Hsieh WY, Lin CH, Lin TC, et al. Development and efficacy of lateral flow point-of-care testing devices for rapid and mass COVID-19 diagnosis by the detections of SARS-CoV-2 antigen and anti-SARS-CoV-2 antibodies. Diagnostics 2021; 11(10): 1760.
[http://dx.doi.org/10.3390/diagnostics11101760] [PMID: 34679458]
[79]
Joung J, Ladha A, Saito M, et al. Detection of SARS-CoV-2 with SHERLOCK one-pot testing. N Engl J Med 2020; 383(15): 1492-4.
[http://dx.doi.org/10.1056/NEJMc2026172] [PMID: 32937062]
[80]
Ray SK, Mukherjee S. Genome Editing with CRISPR-Cas9: A budding biological contrivance for colorectal carcinoma research and its perspective in molecular medicine. Curr Mol Med 2021; 21(6): 462-75.
[http://dx.doi.org/10.2174/1566524020666201119143943] [PMID: 33213345]
[81]
Jolany VS, Katalani C, Boone HA, Hajizade A, Sijercic A, Ahmadian G. CRISPR-Based diagnosis of infectious and noninfectious diseases. Biol Proced Online 2020; 22(1): 22.
[http://dx.doi.org/10.1186/s12575-020-00135-3] [PMID: 32939188]
[82]
Rahman MR, Hossain MA, Mozibullah M, et al. CRISPR is a useful biological tool for detecting nucleic acid of SARS-CoV-2 in human clinical samples. Biomed Pharmacother 2021; 140: 111772.
[http://dx.doi.org/10.1016/j.biopha.2021.111772] [PMID: 34062417]
[83]
Broughton JP, Deng X, Yu G, et al. CRISPR–Cas12-based detection of SARS-CoV-2. Nat Biotechnol 2020; 38(7): 870-4.
[http://dx.doi.org/10.1038/s41587-020-0513-4] [PMID: 32300245]
[84]
Kaminski MM, Abudayyeh OO, Gootenberg JS, Zhang F, Collins JJ. CRISPR-based diagnostics. Nat Biomed Eng 2021; 5(7): 643-56.
[http://dx.doi.org/10.1038/s41551-021-00760-7] [PMID: 34272525]
[85]
Aquino-Jarquin G. Recent progress on rapid SARS-CoV-2/COVID-19 detection by CRISPR-Cas13-based platforms. Drug Discov Today 2021; 26(8): 2025-35.
[http://dx.doi.org/10.1016/j.drudis.2021.06.005] [PMID: 34147688]
[86]
Arizti-Sanz J, Bradley AD, Zhang YB, et al. Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants. Nat Biomed Eng 2022; 6(8): 932-43.
[http://dx.doi.org/10.1038/s41551-022-00889-z] [PMID: 35637389]
[87]
Fozouni P, Son S, Díaz de León DM, et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell 2021; 184(2): 323-333.e9.
[http://dx.doi.org/10.1016/j.cell.2020.12.001] [PMID: 33306959]
[88]
Aralis Z, Rauch JN, Audouard M, et al. CREST, a cas13‐based, rugged, equitable, scalable testing (CREST) for SARS‐CoV‐2 detection in patient samples. Curr Protoc 2022; 2(2): e385.
[http://dx.doi.org/10.1002/cpz1.385] [PMID: 35195954]
[89]
Azhar M, Phutela R, Kumar M, et al. Rapid and accurate nucleobase detection using FnCas9 and its application in COVID-19 diagnosis. Biosens Bioelectron 2021; 183: 113207.
[http://dx.doi.org/10.1016/j.bios.2021.113207] [PMID: 33866136]
[90]
Igloi Z, Velzing J, Huisman R, et al. Clinical evaluation of the SD biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients. PLoS One 2021; 16(12): e0260894.
[http://dx.doi.org/10.1371/journal.pone.0260894] [PMID: 34936659]
[91]
Rasmi Y, Li X, Khan J, Ozer T, Choi JR. Emerging point-of-care biosensors for rapid diagnosis of COVID-19: Current progress, challenges, and future prospects. Anal Bioanal Chem 2021; 413(16): 4137-59.
[http://dx.doi.org/10.1007/s00216-021-03377-6] [PMID: 34008124]
[92]
Kim S, Lee JH. Current advances in paper-based biosensor technologies for rapid COVID-19 diagnosis. Biochip J 2022; 16(4): 376-96.
[http://dx.doi.org/10.1007/s13206-022-00078-9] [PMID: 35968255]
[93]
Brazaca LC, dos Santos PL, de Oliveira PR, et al. Biosensing strategies for the electrochemical detection of viruses and viral diseases – A review. Anal Chim Acta 2021; 1159: 338384.
[http://dx.doi.org/10.1016/j.aca.2021.338384] [PMID: 33867035]
[94]
Castillo-Henríquez L, Brenes-Acuña M, Castro-Rojas A, Cordero-Salmerón R, Lopretti-Correa M, Vega-Baudrit JR. Biosensors for the detection of bacterial and viral clinical pathogens. Sensors 2020; 20(23): 6926.
[http://dx.doi.org/10.3390/s20236926] [PMID: 33291722]
[95]
Gardy JL, Loman NJ. Towards a genomics-informed, real-time, global pathogen surveillance system. Nat Rev Genet 2018; 19(1): 9-20.
[http://dx.doi.org/10.1038/nrg.2017.88] [PMID: 29129921]
[96]
Gwinn M, MacCannell D, Armstrong GL. Next-generation sequencing of infectious pathogens. JAMA 2019; 321(9): 893-4.
[http://dx.doi.org/10.1001/jama.2018.21669] [PMID: 30763433]
[97]
Armstrong GL, MacCannell DR, Taylor J, et al. Pathogen genomics in public health. N Engl J Med 2019; 381(26): 2569-80.
[http://dx.doi.org/10.1056/NEJMsr1813907] [PMID: 31881145]
[98]
Barzon L, Lavezzo E, Costanzi G, Franchin E, Toppo S, Palù G. Next-generation sequencing technologies in diagnostic virology. J Clin Virol 2013; 58(2): 346-50.
[http://dx.doi.org/10.1016/j.jcv.2013.03.003] [PMID: 23523339]
[99]
Campos GS, Sardi SI, Falcao MB, et al. Ion torrent-based nasopharyngeal swab metatranscriptomics in COVID-19. J Virol Methods 2020; 282: 113888.
[http://dx.doi.org/10.1016/j.jviromet.2020.113888] [PMID: 32445875]
[100]
Moore SC, Penrice-Randal R, Alruwaili M, et al. Amplicon based MinION sequencing of SARS-CoV-2 and meta-genomics characterisation of nasopharyngeal swabs from patients with COVID-19. MedRxiv 2020.
[http://dx.doi.org/10.1101/2020.03.05.20032011]
[101]
Handel AS, Muller WJ, Planet PJ. Metagenomic next-generation sequencing (mNGS): SARS-CoV-2 as an example of the technology’s potential pediatric infectious disease applications. J Pediatric Infect Dis Soc 2021; 10 (Suppl. 4): S69-70.
[http://dx.doi.org/10.1093/jpids/piab108] [PMID: 34951468]
[102]
Chen X, Kang Y, Luo J, et al. Next-generation sequencing reveals the progression of COVID-19. Front Cell Infect Microbiol 2021; 11: 632490.
[http://dx.doi.org/10.3389/fcimb.2021.632490] [PMID: 33777844]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy